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High-dose therapy with ASCT is an established therapy for
relapsed Non-Hodgkins (NHL) and Hodgkin's lym-
phoma (HL). Randomized trials have shown a benefit for
this approach when compared to standard dose salvage
therapy for HIV-negative NHL. Since these first trials,
transplant-related mortality (TRM) has decreased due to
the use of peripheral stem cells and improved supportive
care. Concomitantly, the treatment of HIV infection has
also improved. Highly active antiretroviral therapy
(HAART) has improved hematologic and immune func-
tion in HIV positive patients. In addition, with the use of
HAART and prophylactic antibiotics, the incidence of
opportunistic infections has greatly decreased. This
improvement in control of OIs and immunologic func-
tion in HIV infected patients due to HAART set the plat-
form for the use of ASCT in patients with high-risk ARL.
Herein we report the long-term follow-up of 32 patients
with ARL who underwent ASCT at the City of Hope Can-
cer Center between 1998 and 2007. Median age at ASCT
was 42 years. Histologies included Diffuse large cell n =
16, Burkitts n = 9, Anaplastic large cell n = 2, HL n = 5. The
conditioning regimen consisted of CBV (carmustine 450
mg/m2, cyclophosphamide (CY) 100 mg/kg, VP16 60
mg/kg) in 28 patients and FTBI 1200 cGY/CY 100 mg/kg/
VP16 60 mg/kg in 4 patients, All patients engrafted at a
median of 10 days to an ANC >500 (range 5–19 days).
One patient died of regimen-related cardiac toxicity.
Other regimen-related toxicities included grade 3–4
hepatic toxicity n = 3, interstitial pneumonitis n = 2. OI's
included PCP pneumonia in 2 patients who were not
compliant with prophylaxis, CMV infection n = 3, VZV n
= 2. One case of treatment related myelodysplasia was
seen and the patient ultimately died of myelodysplasia
while in remission from his ARL. Median HIV viral load at
ASCT was 5726 copies/ml, with 25 patients having an
undetectable viral load. Median CD4 count at ASCT was
156 (range 25–1064), which rose to 420 (range 95–1164)
at 2-year follow-up. Only 10 patients had an undetectable
VL at 2 years. Three patients who were in remission were
lost to follow-up after 4 years. Median f/u for the entire
group is 47 (range 0.7–104) months. Two-year overall
survival is 80 percent (95% CI 66–89) and progression-
free survival (PFS) is 81 percent (95% CI 67–90). In con-
clusion, this large single institution series of ASCT in ARL
demonstrates that the procedure has low transplant-
related mortality and can lead to long-term remission
without deleterious effects on the underlying HIV infec-
tion.
from 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical 
Research
Bethesda, MD, USA. 6–7 October 2008
Published: 17 June 2009
Infectious Agents and Cancer 2009, 4(Suppl 2):O14 doi:10.1186/1750-9378-4-S2-O14
<supplement> <title> <p>Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research</p> </title> <sponsor> <note>Publication of this supplement was made possible with support from the Office of HIV and AIDS Malignancy, National Cancer Institute, National Institutes of Health.</note> </sponsor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1750-9378-4-S2-full.pdf">here</a>.</note> url>http://www.biomedcentral.com/content/pdf/1750-9378-4-S2-info.pdf</url> </supplement>
This abstract is available from: http://www.infectagentscancer.com/content/4/S2/O14
© 2009 Krishnan et al; licensee BioMed Central Ltd. 
